Ultragenyx's Angelman Syndrome Therapy Fails Phase 3 Trial
Source Summary
Ultragenyx announced that its experimental therapy for Angelman syndrome, a rare genetic disorder, demonstrated no benefit over sham treatment in a Phase 3 clinical trial. The failed trial represents a significant setback for the company's development program in this rare disease indication.
Why it matters
Failed late-stage trials can significantly impact a company's stock price, pipeline value, and strategic direction in drug development.
